Items Tagged ‘Stage IV Liver Cancer’

May 27th, 2014

Liver Cancer Drug Livatag® Granted U.S. Food and Drug Administration Fast Track Designation

By

The drug Livatag® (doxorubicin Transdrug™) has received fast-track designation from the U.S. Food and Drug Administration (FDA) for the treatment of primary liver cancer after treatment with Nexavar® (sorafenib). This was recently announced in a press release from BioAlliance Pharma SA, manufacturers of Livatag.[1] The liver is the largest organ in the body and is […]

View full entry

Tags: Liver Cancer, News, Recurrent Liver Cancer, Stage IV Liver Cancer


June 23rd, 2011

Nexavar Superior to Sutent in Liver Cancer

By

Nexavar® (sorafenib) provides superior overall survival to Sutent® (sunitinib) in the treatment of hepatocellular (liver) cancer. These results were presented at the 2011 annual American Society of Clinical Oncology (ASCO) meeting. Hepatocellular carcinoma is the most common type of primary liver cancer (cancer that begins in the liver). Factors that increase the risk of developing […]

View full entry

Tags: Liver Cancer, News, Stage IV Liver Cancer, Stages I-III Liver Cancer


May 31st, 2011

Cabozantinib Shows Promise against Bone Metastases

By

The investigational drug cabozantinib is showing promise against several types of advanced cancer, and may also reduce or eliminate bone metastases (cancer that has spread to the bone) in some patients. These results will be presented at the 2011 annual meeting of the American Society of Clinical Oncology. Metastatic cancer refers to cancer that has […]

View full entry

Tags: Breast Cancer, Liver Cancer, Melanoma, Metastatic Breast Cancer, News, Ovarian Cancer, Prostate Cancer, Recurrent Breast Cancer, Recurrent Liver Cancer, Recurrent Melanoma, Recurrent Ovarian Cancer, Refactory/Recurrent Prostate Cancer


May 2nd, 2011

FDA Grants Orphan Drug Status to Investigational Liver Cancer Drug

By

PV-10—an investigational liver cancer drug—has been designated an orphan drug by the US Food and Drug Administration (FDA). The orphan drug designation is intended to encourage the development of drugs for rare diseases by providing incentives for drug development. PV-10 is an injectable formulation of Rose Bengal, a compound that has a long history of […]

View full entry

Tags: Liver Cancer, News, Stage IV Liver Cancer